GSK’s attempt to develop the first vaccine for herpes simplex virus (HSV) has ended in failure, leaving the race open for the ...

The company reported Health Canada authorized the use of its Spikevax KP.2 shot for those aged six months and older. Last ...

BioNTech has been boosted a wave of enthusiasm over another company’s cancer drug, which has turned the biopharma industry ...

GSK Plc has halted development of its herpes simplex virus vaccine, GSK3943104, after it failed to meet efficacy goals in ...

The latest flu vaccines are now available, and just like the COVID-19 shots, it's recommended to get the flu shot in ...

The revamped vaccine is an effort by regulators and vaccine makers to keep pace with the virus, which continues to evolve ...

Evercore ISI analyst Cory Kasimov maintained a Hold rating on BioNTech SE (BNTX – Research Report) today and set a price target of ...

The latest, highly contagious subvariants are driving infections, but new vaccines may help stem the tide of another wave — ...

Moderna, Inc.’s (NASDAQ:MRNA) manufacturing facility in Laval, Quebec, received a Drug Establishment License (DEL) from ...

Moderna's Spikevax KP.2 targets the KP.2 variant of the virus. The U.S. Food and Drug Administration has also approved the shot, as well as updated vaccines from Pfizer and BioNTech. Moderna (MRNA ...

These extra doses will bring more highly specialised work making these novel molecules to contract manufacturing ...